BNP Paribas Financial Markets Sells 18,673 Shares of Cryoport, Inc. (NASDAQ:CYRX)

BNP Paribas Financial Markets cut its stake in shares of Cryoport, Inc. (NASDAQ:CYRX) by 41.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,336 shares of the company’s stock after selling 18,673 shares during the period. BNP Paribas Financial Markets’ holdings in Cryoport were worth $214,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd bought a new position in Cryoport in the 3rd quarter worth $82,000. Algert Global LLC increased its stake in Cryoport by 282.7% in the 3rd quarter. Algert Global LLC now owns 247,483 shares of the company’s stock worth $2,007,000 after acquiring an additional 182,808 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Cryoport by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock valued at $3,144,000 after purchasing an additional 2,226 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Cryoport during the 3rd quarter valued at about $105,000. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Cryoport in the 3rd quarter valued at approximately $326,000. 92.90% of the stock is currently owned by institutional investors.

Cryoport Stock Performance

Shares of Cryoport stock opened at $7.72 on Tuesday. The firm has a market capitalization of $381.61 million, a P/E ratio of -2.28 and a beta of 1.62. Cryoport, Inc. has a 52 week low of $5.32 and a 52 week high of $20.10. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The company has a 50 day moving average price of $7.31 and a 200 day moving average price of $8.06.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on CYRX shares. UBS Group boosted their target price on Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, October 18th. Roth Mkm reduced their price target on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.50.

Insider Transactions at Cryoport

In related news, Director Ramkumar Mandalam sold 7,369 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the sale, the director now directly owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. This represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $6.51, for a total transaction of $325,500.00. Following the sale, the chief executive officer now directly owns 731,897 shares in the company, valued at approximately $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,869 shares of company stock worth $735,673. Company insiders own 10.10% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.